Sequenom Says Genetic Test Predicts Progression Risk
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.